Literature DB >> 16190864

Salivary agglutinin and lung scavenger receptor cysteine-rich glycoprotein 340 have broad anti-influenza activities and interactions with surfactant protein D that vary according to donor source and sialylation.

Kevan L Hartshorn1, Antoon Ligtenberg, Mitchell R White, Martin Van Eijk, Max Hartshorn, Lily Pemberton, Uffe Holmskov, Erika Crouch.   

Abstract

We previously found that scavenger receptor cysteine-rich gp-340 (glycoprotein-340), isolated from lung or saliva, directly inhibits human IAVs (influenza A viruses). We now show that salivary gp-340 has broad antiviral activity against human, equine and porcine IAV strains. Although lung and salivary gp-340 are identical in protein sequence, salivary gp-340 from one donor had significantly greater antiviral activity against avian-like IAV strains which preferentially bind sialic acids in alpha(2,3) linkage. A greater density of alpha(2,3)-linked sialic acids was present on the salivary gp-340 from this donor as compared with salivary gp-340 from another donor or several preparations of lung gp-340. Hence, the specificity of sialic acid linkages on gp-340 is an important determinant of anti-IAV activity. Gp-340 binds to SP-D (surfactant protein D), and we previously showed that lung gp-340 has co-operative interactions with SP-D in viral neutralization and aggregation assays. We now report that salivary gp-340 can, in some cases, strongly antagonize certain antiviral activities of SP-D. This effect was associated with greater binding of salivary gp-340 to the carbohydrate recognition domain of SP-D as compared with the binding of lung gp-340. These findings may relate to inter-individual variations in innate defence against highly pathogenic IAV and to effects of aspiration of oral contents on SP-D-mediated lung functions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16190864      PMCID: PMC1360705          DOI: 10.1042/BJ20050695

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  51 in total

1.  Salivary agglutinin, which binds Streptococcus mutans and Helicobacter pylori, is the lung scavenger receptor cysteine-rich protein gp-340.

Authors:  A Prakobphol; F Xu; V M Hoang; T Larsson; J Bergstrom; I Johansson; L Frängsmyr; U Holmskov; H Leffler; C Nilsson; T Borén; J R Wright; N Strömberg; S J Fisher
Journal:  J Biol Chem       Date:  2000-12-22       Impact factor: 5.157

2.  Influenza A virus NS1 protein prevents activation of NF-kappaB and induction of alpha/beta interferon.

Authors:  X Wang; M Li; H Zheng; T Muster; P Palese; A A Beg; A García-Sastre
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Collectin-mediated antiviral host defense of the lung: evidence from influenza virus infection of mice.

Authors:  P C Reading; L S Morey; E C Crouch; E M Anders
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Localization of lung surfactant protein D on mucosal surfaces in human tissues.

Authors:  J Madsen; A Kliem; I Tornoe; K Skjodt; C Koch; U Holmskov
Journal:  J Immunol       Date:  2000-06-01       Impact factor: 5.422

5.  Pulmonary surfactant proteins A and D enhance neutrophil uptake of bacteria.

Authors:  K L Hartshorn; E Crouch; M R White; M L Colamussi; A Kakkanatt; B Tauber; V Shepherd; K N Sastry
Journal:  Am J Physiol       Date:  1998-06

6.  Influenza and the rates of hospitalization for respiratory disease among infants and young children.

Authors:  H S Izurieta; W W Thompson; P Kramarz; D K Shay; R L Davis; F DeStefano; S Black; H Shinefield; K Fukuda
Journal:  N Engl J Med       Date:  2000-01-27       Impact factor: 91.245

7.  Enhanced antiviral and opsonic activity of a human mannose-binding lectin and surfactant protein D chimera.

Authors:  M R White; E Crouch; D Chang; K Sastry; N Guo; G Engelich; K Takahashi; R A Ezekowitz; K L Hartshorn
Journal:  J Immunol       Date:  2000-08-15       Impact factor: 5.422

8.  Site-directed mutagenesis of Cys-15 and Cys-20 of pulmonary surfactant protein D. Expression of a trimeric protein with altered anti-viral properties.

Authors:  P Brown-Augsburger; K Hartshorn; D Chang; K Rust; C Fliszar; H G Welgus; E C Crouch
Journal:  J Biol Chem       Date:  1996-06-07       Impact factor: 5.157

9.  Interactions of recombinant human pulmonary surfactant protein D and SP-D multimers with influenza A.

Authors:  K Hartshorn; D Chang; K Rust; M White; J Heuser; E Crouch
Journal:  Am J Physiol       Date:  1996-11

10.  Increased susceptibility of diabetic mice to influenza virus infection: compromise of collectin-mediated host defense of the lung by glucose?

Authors:  P C Reading; J Allison; E C Crouch; E M Anders
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

View more
  28 in total

1.  Comparison of N-linked Glycoproteins in Human Whole Saliva, Parotid, Submandibular, and Sublingual Glandular Secretions Identified using Hydrazide Chemistry and Mass Spectrometry.

Authors:  Prasanna Ramachandran; Pinmanee Boontheung; Eric Pang; Weihong Yan; David T Wong; Joseph A Loo
Journal:  Clin Proteomics       Date:  2008-12       Impact factor: 3.988

2.  Genetic analysis of H1N1 influenza virus from throat swab samples in a microfluidic system for point-of-care diagnostics.

Authors:  B Scott Ferguson; Steven F Buchsbaum; Ting-Ting Wu; Kuangwen Hsieh; Yi Xiao; Ren Sun; H Tom Soh
Journal:  J Am Chem Soc       Date:  2011-05-24       Impact factor: 15.419

3.  Introduction of N-linked glycans in the lectin domain of surfactant protein D: impact on interactions with influenza A viruses.

Authors:  Martin van Eijk; Laurie Bruinsma; Kevan L Hartshorn; Mitchell R White; Michael J Rynkiewicz; Barbara A Seaton; Wieger Hemrika; Roland A Romijn; Bas W van Balkom; Henk P Haagsman
Journal:  J Biol Chem       Date:  2011-04-13       Impact factor: 5.157

4.  A unique sugar-binding site mediates the distinct anti-influenza activity of pig surfactant protein D.

Authors:  Martin van Eijk; Michael J Rynkiewicz; Mitchell R White; Kevan L Hartshorn; Xueqing Zou; Klaus Schulten; Dong Luo; Erika C Crouch; Tanya R Cafarella; James F Head; Henk P Haagsman; Barbara A Seaton
Journal:  J Biol Chem       Date:  2012-06-08       Impact factor: 5.157

5.  Hexapeptide libraries for enhanced protein PTM identification and relative abundance profiling in whole human saliva.

Authors:  Sricharan Bandhakavi; Susan K Van Riper; Pierre N Tawfik; Matthew D Stone; Tufia Haddad; Nelson L Rhodus; John V Carlis; Timothy J Griffin
Journal:  J Proteome Res       Date:  2011-01-14       Impact factor: 4.466

6.  Innate immunity to influenza virus: implications for future therapy.

Authors:  Mitchell R White; Mona Doss; Patrick Boland; Tesfaldet Tecle; Kevan L Hartshorn
Journal:  Expert Rev Clin Immunol       Date:  2008-07-01       Impact factor: 4.473

7.  Multiple components contribute to ability of saliva to inhibit influenza viruses.

Authors:  M R White; E J Helmerhorst; A Ligtenberg; M Karpel; T Tecle; W L Siqueira; F G Oppenheim; K L Hartshorn
Journal:  Oral Microbiol Immunol       Date:  2009-02

8.  Leucine-rich repeats of bacterial surface proteins serve as common pattern recognition motifs of human scavenger receptor gp340.

Authors:  Vuokko Loimaranta; Jukka Hytönen; Arto T Pulliainen; Ashu Sharma; Jorma Tenovuo; Nicklas Strömberg; Jukka Finne
Journal:  J Biol Chem       Date:  2009-05-22       Impact factor: 5.157

9.  gp340 promotes transcytosis of human immunodeficiency virus type 1 in genital tract-derived cell lines and primary endocervical tissue.

Authors:  Earl Stoddard; Houping Ni; Georgetta Cannon; Chunhui Zhou; Neville Kallenbach; Daniel Malamud; Drew Weissman
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

10.  Human H-ficolin inhibits replication of seasonal and pandemic influenza A viruses.

Authors:  Anamika Verma; Mitchell White; Vinod Vathipadiekal; Shweta Tripathi; Julvet Mbianda; Micheal Ieong; Li Qi; Jeffery K Taubenberger; Kazue Takahashi; Jens C Jensenius; Steffen Thiel; Kevan L Hartshorn
Journal:  J Immunol       Date:  2012-07-30       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.